Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.92 |
---|---|
High | 2.92 |
Low | 2.92 |
Bid | 2.76 |
Offer | 2.96 |
Previous close | 3.06 |
Average volume | 1.51k |
---|---|
Shares outstanding | 996.09m |
Free float | 900.66m |
P/E (TTM) | -- |
Market cap | 24.35bn HKD |
EPS (TTM) | -2.39 HKD |
Data delayed at least 15 minutes, as of Nov 13 2024 07:15 GMT.
More ▼
Press releases
- Zai Lab Announces Third Quarter 2024 Financial Results and Recent Corporate Updates
- Zai Lab and argenx Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in China
- Zai Lab Reports Positive Topline Data from Phase 3 Bridging Trial Evaluating KarXT for the Treatment of Schizophrenia in China
- ZL-1310, an Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC), Demonstrates Promising Objective Response Rates and Safety Profile in Extensive-Stage Small Cell Lung Cancer
- Zai Lab Announces Participation in November and December Investor Conferences
- Zai Lab to Host Webcast Presentation to Discuss Data from Early Clinical Program Evaluating Its Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310
- Zai Lab to Announce Third Quarter 2024 Financial Results and Recent Corporate Updates on November 12, 2024
- Zai Lab to Present Data from Phase 1 Trial of ZL-1310, Its Investigational Antibody-Drug Conjugate (ADC) for DLL3+ Solid Tumors, at EORTC-NCI-AACR Symposium (ENA) 2024
- Zai Lab to Present Preclinical Data of ZL-1503, an IL-13/IL-31 Bispecific Antibody for the Treatment of Atopic Dermatitis, at EADV Congress 2024
- Zai Lab to Present Preliminary Data From Phase 1 Trial of ZL-1218, an Investigational Anti-CCR8 Antibody for the Treatment of Advanced Solid Tumors, at ESMO Congress 2024
More ▼